In March 2025, the company introduced new options for a immediate-to-customer offering of its Wegovy weight loss drug. The company proven a different pharmacy, identified as NovoCare, which might cost consumers $499 each month for use of the drug, fewer than fifty percent the price of the drug by means of other pharmaceutical distribution networks.